Laboratory of Tropical Diseases-Prof. Dr. Luiz Jacintho da Silva, Department of Genetics, Evolution, Microbiology and Immunology, University of Campinas-UNICAMP, Campinas, SP, Brazil.
Instituto Carlos Chagas, Fundação Oswaldo Cruz - FIOCRUZ, Curitiba, PR, Brazil.
Malar J. 2018 Oct 31;17(1):401. doi: 10.1186/s12936-018-2543-7.
BACKGROUND: The genetic diversity of malaria antigens often results in allele variant-specific immunity, imposing a great challenge to vaccine development. Rhoptry Neck Protein 2 (PvRON2) is a blood-stage antigen that plays a key role during the erythrocyte invasion of Plasmodium vivax. This study investigates the genetic diversity of PvRON2 and the naturally acquired immune response to P. vivax isolates. RESULTS: Here, the genetic diversity of PvRON2 and the naturally acquired humoral immune response against PvRON2 in infected and non-infected individuals from a vivax malaria endemic area in Brazil was reported. The diversity analysis of PvRON2 revealed that the protein is conserved in isolates in Brazil and worldwide. A total of 18 (19%) patients had IgG antibodies to PvRON2. Additionally, the analysis of the antibody response in individuals who were not acutely infected with malaria, but had been infected with malaria in the past indicated that 32 patients (33%) exhibited an IgG immune response against PvRON2. CONCLUSIONS: PvRON2 was conserved among the studied isolates. The presence of naturally acquired antibodies to this protein in the absence of the disease suggests that PvRON2 induces a long-term antibody response. These results indicate that PvRON2 is a potential malaria vaccine candidate.
背景:疟原虫抗原的遗传多样性通常导致等位基因变异特异性免疫,这对疫苗的开发构成了巨大的挑战。裂殖体颈蛋白 2(PvRON2)是一种血期抗原,在间日疟原虫入侵红细胞的过程中起着关键作用。本研究调查了 PvRON2 的遗传多样性以及对间日疟原虫分离株的天然获得性免疫反应。
结果:本研究报道了巴西间日疟流行地区感染和未感染个体中 PvRON2 的遗传多样性和对 PvRON2 的天然体液免疫反应。PvRON2 的多样性分析表明,该蛋白在巴西和全球的分离株中是保守的。共有 18 名(19%)患者对 PvRON2 具有 IgG 抗体。此外,对过去曾感染过疟疾但目前未急性感染疟疾的个体的抗体反应分析表明,32 名患者(33%)对 PvRON2 表现出 IgG 免疫反应。
结论:在所研究的分离株中,PvRON2 是保守的。在没有疾病的情况下,这种蛋白存在天然获得的抗体,这表明 PvRON2 诱导了长期的抗体反应。这些结果表明 PvRON2 是一种潜在的疟疾疫苗候选物。
Front Cell Infect Microbiol. 2018-5-15
Malar J. 2011-3-14
Front Immunol. 2022
Can J Infect Dis Med Microbiol. 2022-10-7
Sci Rep. 2020-10-7
PLoS Negl Trop Dis. 2020-7-8
Front Cell Infect Microbiol. 2018-5-15
NPJ Vaccines. 2017